Internal Medicine, Hematology & Oncology · Saint Louis, MO
NPI
1750427480
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5th, 6th, 8th Fl
Saint Louis, MO, 63108
Phone (314) 454-8304
Groups this clinician bills Medicare through
Medicare paid, 2024
$824K
38,195 services
Medicare patients, 2024
262
Average age 69
Drug cost, 2024
$2.2M
775 prescriptions
Company payments, 2025
$4,786
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Geoffrey L Uy was code J1453 (injection, fosaprepitant, 1 mg), 2,700 times for 13 patients. In total Geoffrey L Uy billed 38,195 services in 117 codes, and Medicare paid $824K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 2,700 | 13 | $0.11 | $285 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 530 | 31 | $0.09 | $48.93 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 340 | 25 | $0.83 | $282 |
| 99233 Hospital E&M - Subsequent | Facility | 166 | 44 | $90.85 | $15K |
| 99232 Hospital E&M - Subsequent | Facility | 149 | 45 | $60.40 | $9,000 |
| 99214 Office E&M - Established | Office | 117 | 54 | $93.56 | $11K |
| 96413 Chemotherapy Administration | Office | 112 | 76 | $92.04 | $10K |
| 96375 Injection Administration | Office | 84 | 41 | $11.42 | $959 |
| 96367 Intravenous Infusion, Hydration | Office | 67 | 32 | $21.32 | $1,428 |
| 36415 Venipuncture Blood Collection | Office | 66 | 35 | $8.65 | $571 |
| 96372 Injection Administration | Office | 36 | 28 | $10.87 | $391 |
| 96417 Chemotherapy Administration | Office | 25 | 16 | $47.71 | $1,193 |
| 96415 Chemotherapy Administration | Office | 19 | 11 | $20.83 | $396 |
| 96365 Intravenous Infusion, Hydration | Office | 17 | 15 | $44.31 | $753 |
| J3490 Unclassified drugs | Office | 17 | 12 | $0.61 | $10.31 |
By year: 2022 $1.2M for 64,921 services; 2023 $1.1M for 45,132 services; 2024 $824K for 38,195 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 66 | 35 | $8.65 | $571 |
Medicare prescription drug claims, 2024
In 2024, the drug Geoffrey L Uy prescribed most often to Medicare patients was Acyclovir, with 74 prescriptions and refills. In total Geoffrey L Uy wrote 775 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 74 | 110 | 22 | $1,224 |
| Fluconazole Generic | 58 | 70 | 16 | $6,370 |
| Sprycel Dasatinib | 51 | 51 | Under 11 | $701K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 48 | 62 | 12 | $202 |
| Valacyclovir Valacyclovir Hcl | 44 | 70 | 12 | $1,882 |
| Gabapentin Generic | 27 | 35 | Under 11 | $253 |
| Ciprofloxacin Hcl Generic | 27 | 33 | 13 | $336 |
| Prochlorperazine Maleate Generic | 26 | 26 | 14 | $489 |
| Prednisone Generic | 23 | 31 | 11 | $183 |
| Venclexta Venetoclax | 21 | 21 | Under 11 | $127K |
| Dapsone Generic | 21 | 25 | Under 11 | $899 |
| Pantoprazole Sodium Generic | 20 | 28 | Under 11 | $106 |
| Prevymis Letermovir | 16 | 16 | Under 11 | $111K |
| Famotidine Generic | 16 | 26 | Under 11 | $43.7 |
| Allopurinol Generic | 15 | 24 | Under 11 | $123 |
Brand drugs: - claims; generic drugs: 599 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Geoffrey L Uy $4,786 ($4,786 in general payments such as food, travel and fees) from 9 companies. The largest payer was Syndax Pharmaceuticals, Inc. with $4,316.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.